According to market experts acute skin and skin structure infections (ABSSSI) comprise set of bacterial infections that involve multiple layers of the skin and associated tissues. These infections tend to be more severe in nature than simple infections of the skin, and they usually require systemic antibacterial therapy and patient hospitalization.
This report contains market size and forecasts of Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment in Global, including the following market information:
Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Delafloxacin Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment include Furiex Pharmaceuticals, Inc., GlaxoSmithKline plc, Melinta Therapeutics, Inc., Debiopharm International S.A., MerLion Pharmaceuticals Pte Ltd., Durata Therapeutics, Inc., Paratek Pharmaceuticals, Inc., Cempra, Inc. and Abbott Laboratories, Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Segment Percentages, by Type, 2021 (%)
Delafloxacin
Vancomycin
Ceftaroline Fosamil
Others
Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Segment Percentages, by Application, 2021 (%)
Cellulitis
Abscess
Surgical Wounds
Traumatic Wound
Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Furiex Pharmaceuticals, Inc.
GlaxoSmithKline plc
Melinta Therapeutics, Inc.
Debiopharm International S.A.
MerLion Pharmaceuticals Pte Ltd.
Durata Therapeutics, Inc.
Paratek Pharmaceuticals, Inc.
Cempra, Inc.
Abbott Laboratories, Inc.
Actelion Pharmaceuticals Ltd.
Albany Molecular Research, Inc.
Allergan plc.
AstraZeneca
Bayer AG
Macrolide Pharmaceuticals, Inc.
Merck & Co, Inc.
Pfizer, Inc.
Sanofi
Teva Pharmaceuticals Industries Ltd.
Zavante Therapeutics, Inc.